BIVI Stock Overview
BioVie Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
BioVie Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.48 |
| 52 Week High | US$8.69 |
| 52 Week Low | US$0.45 |
| Beta | 1.21 |
| 1 Month Change | -9.15% |
| 3 Month Change | -47.25% |
| 1 Year Change | -93.93% |
| 3 Year Change | -97.23% |
| 5 Year Change | -96.92% |
| Change since IPO | -98.71% |
Recent News & Updates
Shareholder Returns
| BIVI | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -0.3% | -0.2% | 2.9% |
| 1Y | -93.9% | -1.0% | 22.2% |
Return vs Industry: BIVI underperformed the US Biotechs industry which returned 0.9% over the past year.
Return vs Market: BIVI underperformed the US Market which returned 21.9% over the past year.
Price Volatility
| BIVI volatility | |
|---|---|
| BIVI Average Weekly Movement | 22.3% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: BIVI's share price has been volatile over the past 3 months.
Volatility Over Time: BIVI's weekly volatility (22%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 18 | Cuong Viet Do | bioviepharma.com |
BioVie Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer’s disease, as well as Phase 2 clinical trial for the treatment of Parkinson’s disease. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016.
BioVie Inc. Fundamentals Summary
| BIVI fundamental statistics | |
|---|---|
| Market cap | US$26.62m |
| Earnings (TTM) | -US$43.27m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.6x
P/E RatioIs BIVI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BIVI income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$43.27m |
| Earnings | -US$43.27m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.79 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 136.1% |
How did BIVI perform over the long term?
See historical performance and comparison